P16INK4a as an adjunct marker in liquid-based cervical cytology

International Journal of Cancer

Volumn 108, Issue 6, 2004, Pages 871-876

  Sahebali, Shaira ^a   Depuydt, Christophe E ^b   Segers, Kurt ^b   Moeneclaey, Liliane M ^a   Vereecken, Annie J ^b   Van Marck, Eric ^a   Bogers, Johannes J ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Laboratory for Clinical Pathology (Labo Lokeren Campus RIATOL)   (Belgium)

Author keywords

Cervical cytology; Human papillomavirus; Molecular marker; p16 INK4a; PCR

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P16; PROTEIN P16INK4A; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; DNA DETERMINATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS; BIOSYNTHESIS; GENETIC MARKER; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MASS SCREENING; METABOLISM; METHODOLOGY; PAPILLOMA VIRUS; ROC CURVE; UTERINE CERVIX TUMOR; VIROLOGY;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MASS SCREENING; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 1342263744     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11589     Document Type: Article

References (40)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001;185:308-17.
3. Koss LG. The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989;261:737-43.
4. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
5. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R. Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
6. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
7. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
8. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
9. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
10. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
11. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
12. Miller AB. Natural history of cervical human papillomavirus infections. Lancet 2001;357:1816.
13. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
14. Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, Duensing S, Sheets EE, Munger K, Crum CP. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25:884-91.
15. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
16. Nakao Y, Yang X, Yokoyama M, Ferenczy A, Tang SC, Pater MM, Pater A. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 1997;75:1410-6.
17. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8.
18. Stanley MA. Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res 2002;89:241-8.
19. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
20. Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, Kurman RJ, Schmidt D, Stoler M, von Knebel Doeberitz M. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26:1389-99.
21. Milde-Langosch K, Riethdorf S, Kraus-Poppinghaus A, Riethdorf L, Loning T. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 2001;439:55-61.
22. Riethdorf L, Riethdorf S, Lee KR, Cviko A, Loning T, Crum CP. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol 2002;33:899-904.
23. Cameron RI, Maxwell P, Jenkins D, McCluggage WG. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 2002;41:313-21.
24. Bibbo M, Klump WJ, DeCecco J, Kovatich AJ. Procedure for immunocytochemical detection of P16INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol 2002;46:25-9.
25. Saqi A, Pasha TL, McGrath CM, Yu GH, Zhang P, Gupta P. Overexpression of p16INK4A in liquid-based specimens (SurePath trade mark) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol 2002;27:365-70.
26. Murphy N, Ring M, Killalea AG, Uhlmann V, O'Donovan M, Mulcahy F, Turner M. McGuinness E, Griffin M, Martin C, Sheils O, O'Leary JJ. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 2003:56:56-63.
27. Sahebali S, Depuydt CE, Segers K, Vereecken A, Bogers J. Cervical cytological screening and HPV DNA testing in Flanders. Acta Clin Belg 2003. in press.
28. Depuydt CE, Vereecken AJ, Salembier GM, Vanbrabant AS, Boels LA, Van Herck E, Arbyn M, Segers K, Bogers JJ. Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. Br J Cancer 2003;88:560-6.
29. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zang T, Scott DR, Rush BB, Lawler P, Sherman ME, Kurman RJ, Manos MM. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
30. Riethmuller D, Gay C, Bertrand X, Bettinger D, Schaal JP, Carbillet JP, Lassabe C, Arveux P, Seilles E, Mougin C. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by hybrid capture II and polymerase chain reaction. Diagn Mol Pathol 1999;8:157-64.
31. Vassilakos P, Saurel J, Rondez R. Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories. Acta Cytol 1999;43:65-8.
32. Smith JH. Bethesda 2001. Cytopathology 2002;13:4-10.
33. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
34. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A, Manos MM. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-7.
35. Van den Brule AJ, Meijer CJ, Bakels V. Kenemans P, Walboomers JM. Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. J Clin Microbiol 1990;28:2739-43.
36. Sahebali S, Depuydt CE, Segers K, Vereecken AJ, Van Marck E, Bogers JJ. Ki-67 immunocytochemistry in liquid-based cervical cytology; useful as an adjunctive tool? J Clin Path 2003;56:681-6.
37. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
38. Von Knebel Doeberitz M. New markers for cervical dysplasia to visualize the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-42.
39. Negri G, Egarter-Vigl E, Kasal A, Romano F, Haitel A, Mian C. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol 2003;27:187-93.
40. Giard RW, Coebergh JW. Population screening for cervical cancer: eventual gain not expected to increase by testing for papillomavirus. Ned Tijdschr Geneeskd 2000;144:1664-8.